S1207 Trial of Adjuvant Endocrine Therapy with or without Everolimus for High-Risk, Hormone Receptor-Positive, HER2-Negative Breast Cancer


S1207 Trial of Adjuvant Endocrine Therapy with or without Everolimus for High-Risk, Hormone Receptor-Positive, HER2-Negative Breast Cancer
Slides from a presentation at SABCS 2012 and transcribed comments from recent interviews with Lisa A Carey, MD (1/17/13) and Edith A Perez, MD (1/17/13)
Chavez-MacGregor M et al. S1207: Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor-positive and HER2-neu negative breast cancer (NCT01674140). San Antonio Breast Cancer Symposium 2012;Abstract OT2-2-04.

Dr Carey is Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research, Chief of the Division of Hematology and Oncology, Physician-in-Chief at the North Carolina Cancer Hospital and Associate Director for Clinical Research at the Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina.

Dr Perez is Deputy Director at Large of the Mayo Clinic Cancer Center, Group Vice Chair of the Alliance of Clinical Trials in Oncology and Serene M and Frances C Durling Professor of Medicine at the Mayo Clinic in Jacksonville, Florida.